These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

570 related items for PubMed ID: 22695538

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Plasma S100beta and NSE levels and progression in multiple sclerosis.
    Koch M, Mostert J, Heersema D, Teelken A, De Keyser J.
    J Neurol Sci; 2007 Jan 31; 252(2):154-8. PubMed ID: 17187827
    [Abstract] [Full Text] [Related]

  • 23. Proteomic pattern analysis discriminates among multiple sclerosis-related disorders.
    Komori M, Matsuyama Y, Nirasawa T, Thiele H, Becker M, Alexandrov T, Saida T, Tanaka M, Matsuo H, Tomimoto H, Takahashi R, Tashiro K, Ikegawa M, Kondo T.
    Ann Neurol; 2012 May 31; 71(5):614-23. PubMed ID: 22522477
    [Abstract] [Full Text] [Related]

  • 24. Association between MRI parameters and the MS severity scale: a 12 year follow-up study.
    Minneboo A, Uitdehaag BM, Jongen P, Vrenken H, Knol Dl, van Walderveen MA, Polman CH, Castelijns JA, Barkhof F.
    Mult Scler; 2009 May 31; 15(5):632-7. PubMed ID: 19389751
    [Abstract] [Full Text] [Related]

  • 25. Predicting the severity of relapsing-remitting MS: the contribution of cross-sectional and short-term follow-up MRI data.
    Enzinger C, Fuchs S, Pichler A, Wallner-Blazek M, Khalil M, Langkammer C, Ropele S, Fazekas F.
    Mult Scler; 2011 Jun 31; 17(6):695-701. PubMed ID: 21228028
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. T2 lesions and rate of progression of disability in multiple sclerosis.
    Mostert JP, Koch MW, Steen C, Heersema DJ, De Groot JC, De Keyser J.
    Eur J Neurol; 2010 Dec 31; 17(12):1471-5. PubMed ID: 20500805
    [Abstract] [Full Text] [Related]

  • 29. Secondary-progressive form of multiple sclerosis: MRI changes versus clinical status.
    Masek M, Vaneckova M, Krasensky J, Danes J, Havrdova E, Hrebikova T, Seidl Z.
    Neuro Endocrinol Lett; 2008 Aug 31; 29(4):461-6. PubMed ID: 18766142
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Primary progressive multiple sclerosis diagnostic criteria: a reappraisal.
    Montalban X, Sastre-Garriga J, Filippi M, Khaleeli Z, Téllez N, Vellinga MM, Tur C, Brochet B, Barkhof F, Rovaris M, Miller DH, Polman CH, Rovira A, Thompson AJ.
    Mult Scler; 2009 Dec 31; 15(12):1459-65. PubMed ID: 19995843
    [Abstract] [Full Text] [Related]

  • 32. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.
    Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL.
    JAMA Neurol; 2015 Feb 31; 72(2):152-8. PubMed ID: 25531931
    [Abstract] [Full Text] [Related]

  • 33. Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study.
    Boster A, Hreha S, Berger JR, Bao F, Penmesta R, Tselis A, Endress C, Zak I, Perumal J, Caon C, Vazquez J, Tyler KL, Racke MK, Millis S, Khan O.
    Arch Neurol; 2009 May 31; 66(5):593-9. PubMed ID: 19433659
    [Abstract] [Full Text] [Related]

  • 34. N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry.
    Jasperse B, Jakobs C, Eikelenboom MJ, Dijkstra CD, Uitdehaag BM, Barkhof F, Polman CH, Teunissen CE.
    J Neurol; 2007 May 31; 254(5):631-7. PubMed ID: 17415509
    [Abstract] [Full Text] [Related]

  • 35. Gray matter atrophy in multiple sclerosis: a longitudinal study.
    Fisher E, Lee JC, Nakamura K, Rudick RA.
    Ann Neurol; 2008 Sep 31; 64(3):255-65. PubMed ID: 18661561
    [Abstract] [Full Text] [Related]

  • 36. Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome.
    Kantarci OH, Lebrun C, Siva A, Keegan MB, Azevedo CJ, Inglese M, Tintoré M, Newton BD, Durand-Dubief F, Amato MP, De Stefano N, Sormani MP, Pelletier D, Okuda DT.
    Ann Neurol; 2016 Feb 31; 79(2):288-94. PubMed ID: 26599831
    [Abstract] [Full Text] [Related]

  • 37. ADC measurements in various patterns of multiple sclerosis lesions.
    Phuttharak W, Galassi W, Laopaiboon V, Laopaiboon M, Hesselink JR.
    J Med Assoc Thai; 2006 Feb 31; 89(2):196-204. PubMed ID: 16579006
    [Abstract] [Full Text] [Related]

  • 38. Anti-HHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis.
    Simpson S, Taylor B, Dwyer DE, Taylor J, Blizzard L, Ponsonby AL, Pittas F, Dwyer T, van der Mei I.
    Mult Scler; 2012 Jun 31; 18(6):799-806. PubMed ID: 22084489
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis.
    Frisullo G, Nociti V, Iorio R, Patanella AK, Marti A, Caggiula M, Mirabella M, Tonali PA, Batocchi AP.
    Cytokine; 2008 Oct 31; 44(1):22-5. PubMed ID: 18793860
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.